Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Conferences
Year
All
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
17 October 2024
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
06 March 2024
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
04 March 2024
GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024
10 March 2023
GenSight Biologics to Present at Upcoming Medical Conferences
29 September 2022
GenSight Biologics to Present at Upcoming 2022 Medical Conferences
20 September 2022
GenSight Biologics to Present at Upcoming Industry and Investor Conferences
16 June 2022
GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022
28 Oct 2021 - 29 Oct 2021
Cell UK by Oxford’s Global, London (UK) & Virtual
25 Oct 2021 - 28 Oct 2021
BIO-Europe 2021, Virtual
15 Oct 2021 - 16 Oct 2021
Mitochondrial Diseases Conference 2021 by Mitocon, Virtual
1
2
3
4
5
6
…
12
View next 9 articles
Go back to the page of the page
